Experimental Hematology
Volume 35, Issue 12 , Pages 1839-1846 , December 2007

Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model

  • Evren Alici

      Affiliations

    • Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    • Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    • ,
  • Kyriakos V. Konstantinidis

      Affiliations

    • Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    • Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    • ,
  • Tolga Sutlu

      Affiliations

    • Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    • ,
  • Alar Aints

      Affiliations

    • Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    • Present address for Dr. Aints: Division of Hemato-Oncology, Department of Medicine, Tartu University, Tartu, Estonia, and Competence Centre for Cancer Research, Tallinn, Estonia.
    • ,
  • Gösta Gahrton

      Affiliations

    • Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    • ,
  • Hans-Gustaf Ljunggren

      Affiliations

    • Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    • ,
  • M. Sirac Dilber

      Affiliations

    • Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    • Corresponding Author InformationOffprint requests to: Sirac Dilber, M.D., Ph.D., Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, 14186 Stockholm, Sweden

Received 9 June 2007 ,Revised 31 July 2007 ,Accepted 2 August 2007.

References 

  1. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev. 2002;2:175–187
  2. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol. 2000;18:3031–3037
  3. Gahrton G, Tura S, Ljungman P, et al. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med. 1991;325:1267–1273
  4. Gahrton G. Progress in hematopoietic stem cell transplantation in multiple myeloma. Curr Opin Hematol. 2005;12:463–470
  5. Crawley C, Lalancette M, Szydlo R, et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood. 2005;105:4532–4539
  6. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98:210–216
  7. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. [see comments] N Engl J Med. 1996;335:91–97
  8. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875–1883
  9. Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol. 2006;132:410–451
  10. Li Y, Bendandi M, Deng Y, et al. Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. Blood. 2000;96:2828–2833
  11. Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma—a feasibility study. Blood. 1999;93:2411–2419
  12. Pellat-Deceunynck C. Tumour-associated antigens in multiple myeloma. Br J Haematol. 2003;120:3–9
  13. Turtle CJ, Brown RD, Joshua DE, Hart DN. DC in multiple myeloma immunotherapy. Cytotherapy. 2004;6:128–137
  14. Reichardt VL, Brossart P. Dendritic cells in clinical trials for multiple myeloma. Methods Mol Med. 2005;109:127–136
  15. Trinchieri G. Biology of natural killer cells. Adv Immunol. 1989;47:187–376
  16. Kiessling R, Klein E, Pross H, Wigzell H. “Natural” killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol. 1975;5:117–121
  17. Kiessling R, Klein E, Wigzell H. “Natural” killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol. 1975;5:112–117
  18. Kim S, Prentice HG, Mehta AB, Yokoyama WM. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Br J Haematol. 1990;75:2731–2736
  19. Radl J, De Glopper ED, Schuit HR, Zurcher C. Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice. J Immunol. 1979;122:609–613
  20. Radl J, Croese JW, Zurcher C, Van den Enden-Vieveen MH, de Leeuw AM. Animal model of human disease. Multiple myeloma. Am J Pathol. 1988;132:593–597
  21. Radl J. Age-related monoclonal gammapathies: clinical lessons from the aging C57BL mouse. Immunol Today. 1990;11:234–236
  22. Manning LS, Berger JD, O'Donoghue HL, Sheridan GN, Claringbold PG, Turner JH. A model of multiple myeloma: culture of 5T33 murine myeloma cells and evaluation of tumorigenicity in the C57BL/KaLwRij mouse. Br J Cancer. 1992;66:1088–1093
  23. Radl J. Multiple myeloma and related disorders. Lessons from an animal model. Pathol Biol (Paris). 1999;47:109–114
  24. Alici E, Konstantinidis KV, Aints A, Dilber MS, Abedi-Valugerdi M. Visualization of 5T33 myeloma cells in the C57BL/KaLwRij mouse: establishment of a new syngeneic murine model of multiple myeloma. Exp Hematol. 2004;32:1064–1072
  25. Arase H, Saito T, Phillips JH, Lanier LL. Cutting edge: the mouse NK cell-associated antigen recognized by DX5 monoclonal antibody is CD49b ({alpha}2 integrin, very late antigen-2). J Immunol. 2001;167:1141–1144
  26. Manning LS, Chamberlain NL, Leahy MF, Cordingley FT. Assessment of the therapeutic potential of cytokines, cytotoxic drugs and effector cell populations for the treatment of multiple myeloma using the 5T33 murine myeloma model. Immunol Cell Biol. 1995;73:326–332
  27. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982;155:1823–1841
  28. Wen YJ, Min R, Tricot G, Barlogie B, Yi Q. Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood. 2002;99:3280–3285
  29. Asea , Stein S. Signalling through NK1.1 triggers NK cells to die but induces NK T cells to produce interleukin-4. Immunology. 1998;93:296–305
  30. Wang M, Ellison CA, Gartner JG, HayGlass KT. Natural killer cell depletion fails to influence initial CD4 T cell commitment in vivo in exogenous antigen-stimulated cytokine and antibody responses. J Immunol. 1998;160:1098–1105
  31. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol. 2004;4:665–674
  32. Prabhala RH, Neri P, Bae JE, et al. Dysfunctional T regulatory cells in multiple myeloma. Blood. 2006;107:301–304

PII: S0301-472X(07)00495-X

doi: 10.1016/j.exphem.2007.08.006

Experimental Hematology
Volume 35, Issue 12 , Pages 1839-1846 , December 2007

Article Tools

* Image Usage & Resolution